LumaCell Systems
LumaCell is revolutionizing diagnostics by developing AI-powered biosensor assays that offer bespoke, cost-effective solutions. Their competitive edge lies in a full-stack approach, starting with optimizing custom-designed hardware sensors to improve data input quality for reliable insights. Their platform utilizes genetically modified yeast cells for easy utilization, adaptability, and cost-efficient production. LumaCell's first application is to bridge the gap in drug impairment laws with a precise way to determine active impairment from THC, keeping pace with evolving legalization. Future applications include facilitating real-time measurement of therapeutics like GLP-1 agonists and Cannabinoids for managing chronic diseases such as Type 2 diabetes and chronic pain. LumaCell aims to become a dominant force in GPCR-targeting pharmaceuticals, a sector representing over one-third of the global drug market, by exploring the potential of numerous GPCRs.
LumaCell Systems
LumaCell is revolutionizing diagnostics by developing AI-powered biosensor assays that offer bespoke, cost-effective solutions. Their competitive edge lies in a full-stack approach, starting with optimizing custom-designed hardware sensors to improve data input quality for reliable insights. Their platform utilizes genetically modified yeast cells for easy utilization, adaptability, and cost-efficient production. LumaCell's first application is to bridge the gap in drug impairment laws with a precise way to determine active impairment from THC, keeping pace with evolving legalization. Future applications include facilitating real-time measurement of therapeutics like GLP-1 agonists and Cannabinoids for managing chronic diseases such as Type 2 diabetes and chronic pain. LumaCell aims to become a dominant force in GPCR-targeting pharmaceuticals, a sector representing over one-third of the global drug market, by exploring the potential of numerous GPCRs.